Federal grants to Sparian Biosciences Inc
Sparian Biosciences Inc in New York, New York received $32.0 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Drug Use and Addiction Research Programs, with $32.0 million. In fiscal 2025 it was awarded $7.1 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$32.0 million
- Awards5
- Awarded in FY 2025$7.1 million
- Largest award$13.7 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $4.9 million |
| FY 2022 | 1 | $4.6 million |
| FY 2023 | 2 | $7.4 million |
| FY 2024 | 2 | $8.0 million |
| FY 2025 | 2 | $7.1 million |
Programs that fund Sparian Biosciences Inc
| Program | Awards | Amount |
|---|---|---|
| Drug Use and Addiction Research Programs | 5 | $32.0 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $32.0 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Arylepoxamides: a new class of potent, safer analgesics - the expansion of opioid prescribing in recent years to better treat pain has markedly increased their usage and availability and fueled an epidemic of abuse. Estimates of up to 80% of addicts reported initiating their habit through prescripti | Drug Use and Addiction Research Programs | September 20, 2021 | $13.7 million |
| Development of SBS-226, a mor agonist / dor antagonist, for oud - abstract opioid use disorder (OUD) is a chronic disorder characterized by the repeated, compulsive use of opioid drugs with a detrimental impact to one’s physical, social, and psychological wellbeing. The use of prescription opiates i | Drug Use and Addiction Research Programs | September 20, 2024 | $7.9 million |
| Development of sigma receptor/dat dual-targeting compounds to treat stimulant use disorder - abstract the growing prevalence of stimulant use disorder (STUD) in the us is a major public health concern. As of 2020, 3.2M people had stud in the us, which exceeds the 2.7M people with opioid use disorder | Drug Use and Addiction Research Programs | August 2, 2023 | $6.9 million |
| Clinical development of SBS-147: first-in-class oral arylepoxamide agonist for pain - abstract pain, both acute and chronic, are serious medical conditions that have and continue to significantly drive the growing opioid epidemic in the us. Opioids can be effective analgesics when used appropriately | Drug Use and Addiction Research Programs | June 26, 2025 | $3.1 million |
| Development of cp-analogs as novel treatments for opioid use disorder. - abstract opioid use disorder (OUD) is a chronic disorder characterized by the repeated, compulsive use of opioid drugs with a detrimental impact to one's physical, social, and psychological wellbeing. The use of prescription op | Drug Use and Addiction Research Programs | July 19, 2021 | $316,960 |
Questions people ask
How much federal grant money does Sparian Biosciences Inc get?
$32.0 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Sparian Biosciences Inc the most?
The Department of Health and Human Services, with $32.0 million in 5 awards.
What is Sparian Biosciences Inc's largest federal grant?
$13.7 million under Drug Use and Addiction Research Programs, with its first action in the period on September 20, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in New York
- Metropolitan Transportation Authority
- New York City Housing Authority
- Gateway Development Commission
- The Trustees of Columbia University in the City of New York
- Icahn School of Medicine at Mount Sinai
- New York University
- Inclusiv, Inc
- International Rescue Committee, Inc.
Largest federal grant recipients in New York · Federal grants in New York